title: Peripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.
abstract: BACKGROUND
  Peripheral T-cell lymphoma, unspecified (PTCL-US) is one of the entities from the infrequent family of nodal mature T-cell lymphomas. The clinical course is aggressive, and despite multiagent chemotherapy, the median survival is about 2 years. Published data are limited to retrospective, mostly single-center studies or reviews and usually include more lymphoma subtypes.
  
  
  OBJECTIVE
  To evaluate the current treatment modalities, clinical outcome and prognostic factors in unselected, new diagnosed patients with PTCL-US in the population of the central european region (Czech Republic).
  
  
  METHODS
  Czech Lymphoma Study Group is a national scientific organization which provides an on-line database registry which collects a data about almost all new diagnosed lymphoma patients since year 2000. All diagnostic biopsies were reviewed by a reference pathologist.
  
  
  RESULTS
  We analyzed 63 patients with new diagnosis of PTCL-US. The median age was 59 years (25-81), chemotherapy (CHT) was administered in 56 of the 63 patients: anthracyclin-based CHT in 51%, intensive CHT in 21% and non-anthracyclin regimen was applied in 13% of the patients. The overall response rate was 74.4%, (CR in 57.4%). After a median follow-up of 19.6 months, 41% of the patients were in CR, 3.4% in PR or stable disease and 55% of the patients died. The estimated survival probability in 3 years was 36%. Clinical stage (IV) and CR achievement were found to be independent survival predictors in a multivariate analysis.
  
  
  CONCLUSIONS
  Although the current treatment modalities are mostly ineffective in PTCL-US, appropriate intensive treatment may lead to prolonged remission but not survival.
authors: Department of Hemato-oncology, University Hospital, Olomouc, Czech Republic. vit.prochazka@fnol.cz
authors: Vit
authors: V
authors: Prochazka
authors: Marek
authors: M
authors: Trneny
authors: Robert
authors: R
authors: Pytlik
authors: Ingrid
authors: I
authors: Vasova
authors: Zdenek
authors: Z
authors: Kral
authors: David
authors: D
authors: Belada
authors: Tomas
authors: T
authors: Kozak
authors: Katerina
authors: K
authors: Kubackova
authors: Hana
authors: H
authors: Siffnerova
authors: Milan
authors: M
authors: Matuska
authors: Milan
authors: M
authors: Lysy
authors: Inge
authors: I
authors: Bolomska
authors: Katarina
authors: K
authors: Petrakova
authors: Barbora
authors: B
authors: Otavova
authors: Jana
authors: J
authors: Pribylova
authors: Jirina
authors: J
authors: Svecova
authors: Tomas
authors: T
authors: Papajik
authors: Michaela
authors: M
authors: Hamouzova
authors: Marketa
authors: M
authors: Petrova
authors: Jana
authors: J
authors: Zapletalova
authors: Katerina
authors: K
authors: Langova
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015996:Survival Rate